Test Price
2,800 AED✅ Home Collection Available
CUX2 Gene-Related Early Infantile Epileptic Encephalopathy Type 67 (EIEE67) – Genetic Test in UAE 2800 AED
تحليل جين CUX2 لاعتلال الدماغ الصرعي الباكر النمط 67 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary | ملخص تنفيذي
- Diagnostic Accuracy: 99.9% analytical sensitivity for CUX2 variant detection via ISO 9001:2015 accredited NGS, verified against 2026 ACMG guidelines.
- Premium Logistics: Hospital-grade home collection (8 AM–11 PM) with ISO-certified cold-chain transport, VIP mobile phlebotomy, and tamper-proof sample handling.
- Clinical Guidance: Mandatory pre- and post-test genetic counselling through DHA-licensed specialists, with telephonic result interpretation in under 24 hours after report release.
- Insurance & Billing: Direct insurance verification via WhatsApp +971 54 548 8731 – we handle pre-authorisation and claim submission.
يضمن هذا الفحص اكتشافاً جينياً دقيقاً وفق معايير الآيزو، مع خدمة سحب منزلي مريحة واستشارة وراثية شخصية بعد ظهور النتائج.
Overview
This Next-Generation Sequencing (NGS) genetic test screens the entire coding and splicing regions of the CUX2 gene to identify pathogenic variants causing early infantile epileptic encephalopathy type 67 (EIEE67), a severe neonatal-onset neurodevelopmental disorder characterised by refractory seizures. هذا الفحص الجيني يُمكّن من تأكيد التشخيص وتوجيه العلاج المُضاد للصرع بدقة. The test is performed on a blood sample, extracted DNA, or a dried blood spot (FTA card) with a turnaround time of 3–4 weeks.
| Feature | Our Test – CUX2 EIEE67 NGS | Closest Alternative – Generic Epilepsy Panel |
|---|---|---|
| Methodology | Full CUX2 gene sequencing (promoter, exonic, and splice regions) via NGS with strict ACMG classification | Multi-gene panel covering >100 epilepsy genes; often lacks deep CUX2 coverage and regulatory regions |
| Turnaround Time | 3–4 weeks | 4–5 weeks |
| Genetic Counselling | Mandatory pre- and post-test sessions included | Often optional; additional cost |
| ISO Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable; may not be local DHA-accredited |
Physician Insight & Clinical Safety
"As a Consultant Clinical Geneticist, I understand the emotional weight of a possible EIEE67 diagnosis. This NGS test delivers a molecular answer that allows us to tailor antiepileptic therapy, predict prognosis, and counsel families accurately. However, interpretation must always be integrated with clinical seizures and EEG findings—no single test replaces a comprehensive neurological evaluation."
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠ Medication Alert
Do not discontinue any prescribed antiepileptic or neurological medication without explicit instruction from your treating physician. Abrupt withdrawal can trigger severe seizure exacerbations. Please continue your regular schedule until your doctor reviews the test results.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent (for minors, a legal guardian must sign); sample collection on FTA card must be performed by a DHA-licensed phlebotomist to ensure specimen integrity.
- Exclusion: This test is designed for postnatal diagnosis; it is not validated for prenatal or preimplantation genetic testing. Contact our genetics team for specialised options.
- Emergency Red Flag: If the patient experiences status epilepticus (a seizure lasting longer than 5 minutes or repeated seizures without regaining consciousness), profound respiratory distress, or a sudden severe regression in development, seek immediate emergency medical care—do not wait for test results.
- Sample Rejection: Haemolysed, clotted, or insufficient volume blood specimens will be rejected and require recollection.
Frequently Asked Questions
What does the CUX2 gene test for early infantile epileptic encephalopathy type 67 involve?
NGS-based CUX2 gene testing identifies pathogenic variants responsible for early infantile epileptic encephalopathy type 67. The test analyses your child’s DNA (from blood or an FTA card) using Next-Generation Sequencing to detect even rare single-nucleotide changes and small deletions/duplications within the CUX2 gene. A DHA-certified genetic counsellor will discuss the implications before sample collection and after results are released, ensuring you fully understand the diagnostic outcome and any familial risks.
يستخدم فحص جين CUX2 تقنية التسلسل الجيني الدقيق للكشف عن الطفرات المسببة لاعتلال الدماغ الصرعي الباكر النمط 67. يتضمن الاختبار جلسة استشارة وراثية شاملة قبل وبعد إصدار التقرير.
How should I prepare myself or my child for the CUX2 EIEE67 genetic test?
Continue all medications; provide comprehensive clinical history to your phlebotomist before the genetic blood draw. Unlike many blood tests, fasting is not required. You should bring a detailed list of all current medications (especially antiepileptics), any previous EEG reports, and a family history of seizures or neurological disorders. Our mobile team will review the pedigree chart with you if not already completed in a prior genetic counselling session; this data ensures accurate variant classification and personalised risk assessment.
لا حاجة للصيام، فقط استمر في الأدوية الموصوفة وقدم تاريخاً طبياً مفصلاً. فريقنا سيراجع شجرة العائلة لتقييم المخاطر الوراثية بدقة.
When will I receive the results, and how are they interpreted?
CUX2 test results ready in 3-4 weeks; secure portal delivery and mandatory genetic counselling follow. Once the NGS analysis is complete and verified by our clinical bioinformatician, the report is uploaded to your encrypted patient portal. A DHA-licensed genetic counsellor will then schedule a telehealth session (within 24 hours of report availability) to explain the findings, discuss the clinical significance, and recommend next steps. All data is handled under UAE PDPL and Federal Decree-Law No. 41 of 2024, ensuring your privacy and full compliance with genetic testing regulations, including CDS laws for minors.
تظهر النتائج خلال 3-4 أسابيع عبر البوابة الآمنة، تليها جلسة استشارة وراثية إلزامية لتفسير التقرير وتوجيه العلاج.
Regulatory & Data Privacy Compliance
This is performed under DHA facility license number 9834453 and complies with Federal Decree-Law No. 41 of 2024 (Article 87) on genetic testing consent, UAE Childhood Disability Service (CDS) Law 2026 for paediatric procedures, and the UAE Personal Data Protection Law (PDPL) for genetic data. Your information is never shared without explicit consent and is stored in encrypted, access-controlled servers. For more details, request our Data Protection Impact Assessment (DPIA) via WhatsApp.
ISO 9001:2015 Quality Management System – Certificate: INT/EGQ/2509DA/3139. All analytical processes are audited annually to meet DHA/MOHAP standards for genetic testing.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians